[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemia-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemia-acute":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100644638","addressing-cancer-care-equity-with-social-determinants-of-health-screening-and-early-intervention-100644638",false,"NCT07671209","Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention","ACCESS-Leukemia: Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention","ACCESS","Inclusion Criteria:\n\n1\\. Adult patients ≥18 years who are newly referred to the outpatient Adult Leukemia Treatment Program with the following diagnoses:\n\n1. Acute myeloid leukemia (AML)\n2. Acute lymphoblastic leukemia (ALL)\n3. Intermediate or high-risk myelodysplastic syndrome (MDS), as defined by the revised International Prognostic Scoring System (IPSS-R) and\u002For IPSS-molecular (IPSS-M)\n4. Intermediate or high-risk chronic myelomonocytic leukemia (CMML) by the CMML-specific prognostic scoring system (CPSS-Mol)\n5. Patients with lower risk MDS or CMML may also be included if baseline peripheral blood labs indicate anticipated transfusion dependence, defined as needing ≥2 units of red blood cells every 28 days\n6. Patients with lower risk MDS or CMML may also be included if anticipated visits with the leukemia clinic exceed once per month by primary oncologist\n\n2\\. Ability to complete surveys in English, Spanish, or with assistance of an interpreter.\n\nExclusion Criteria:\n\n1. Adults unable to consent due to lack of capacity based on their leukemia clinician assessment.\n2. Individuals who are not yet adults (infants, children, teenagers).","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to explore if screening health-related social needs and early social work consultation is feasible and acceptable for adults with leukemias. The study examines whether the intervention (ACCESS-Leukemia) improves outcomes. Researchers will compare social determinants of health screening and early involvement of social work to usual care.",[27],"Leukemia, Acute","NOT_YET_RECRUITING","2026-06-22",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":21},"2026-07-15",{"date":36,"type":21},"2027-07-15",{"name":38,"class":39},"Massachusetts General Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":63,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100615733","phase-3-a-trial-to-investigate-whether-oral-arsenic-trioxide-is-similar-to-intravenous-arsenic-trioxide-in-pharmacokinetics-safety-and-efficacy-latitudesdkars-301-100615733","NCT07296445","A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE\u002FSDKARS-301)","LATITUDE - A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High-Risk, Acute Promyelocytic Leukemia","LATITUDE","Key Inclusion Criteria:\n\n* Participants must have diagnosis of newly diagnosed non-high risk APL with a WBC count at diagnosis ≤ 10,000 cells\u002FµL, completed induction with ATO\u002FATRA and achieved morphologic CR with hematologic recovery\n* Eastern Cooperative Oncology Group performance status ≤2\n* Adequate liver, kidney, and cardiac function\n* Have a life expectancy of at least 9 months\n* Negative serum pregnancy test\n\nKey Exclusion Criteria:\n\n* Diagnosis of relapsed or refractory APL.\n* Fridericia's corrected QT interval (QTcF) \\>450 milliseconds (males) and \\>460 milliseconds (females)\n* Any gastrointestinal (GI) issue likely to affect oral drug absorption\u002Fmetabolism or inability to swallow oral medication\n* Prior malignancy or currently receiving treatment for a non-APL malignancy, with the following exceptions: basal cell or squamous cell skin cancer treated with surgical resection, in situ cervical cancer, localized prostate cancer or breast cancer treated with hormone therapy or surgical resection, or other cancer from which the participant has been disease free for at least 2 years.\n* Pregnant or nursing females or is of reproductive potential and unwilling to comply with contraceptive requirements.\n* Participant has known active or chronic hepatitis B or active hepatitis C (HCV) infection or human immunodeficiency virus (HIV)-positive with detectable viral load.\n\nNote: Additional inclusion\u002Fexclusion criteria may apply, per protocol.","12 Years",{"count":50,"type":21},120,[52],"PHASE3","LATITUDE: A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2- Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High Risk, Acute Promyelocytic Leukemia\n\nRationale:\n\nSDK Therapeutics is developing an oral formulation of arsenic trioxide (ATO) for the treatment of acute promyelocytic leukemia (APL). Patients with APL are usually treated with arsenic trioxide (ATO) through an IV along with all-trans retinoic acid (ATRA) taken by mouth. Receiving ATO through an IV requires patients with APL to go to the hospital a lot and get long treatments (sometimes every day over a year of treatment). This can be hard and uncomfortable. If ATO can be taken by mouth, it would be much easier for patients and their families.\n\nObjective:\n\nThe main objective is to show that the body absorbs the same amount of ATO whether it's taken by mouth or through an IV. Other objectives include checking if ATO taken by mouth works just as well, causes fewer heart problems, is safe, and improves quality of life compared with ATO given through an IV.\n\nMain trial endpoints:\n\nThe main endpoint being measured is how much ATO is in the blood after 5 doses. Another important endpoint is how many patients have no signs of cancer in their blood after 3 rounds of treatment.\n\nSecondary trial endpoints:\n\nOther things being measured include: whether patients stay cancer-free over 2 years; changes in heart rhythm; side effects and lab test results; how patients feel during treatment; how much of ATO is in the blood; and how often patients feel bothered by side effects.\n\nTrial design:\n\nThis is an open-label study, meaning everyone knows which treatment they are getting. Patients will get 4 rounds of treatment, each lasting 8 weeks. After that, patients will have check-ups every 3 months to assess safety and disease status for a total of 2 years.\n\nTrial population:\n\nThe study includes adults and teens (12 years and older) who have APL, are not high-risk, and have already finished the first part of their treatment (induction) with IV ATO and ATRA.\n\nInterventions:\n\nThere are 3 groups in the study:\n\nCohort A: Takes 0.15 mg\u002Fkg Oral ATO for 3 rounds, then switches to 0.15 mg\u002Fkg IV ATO for part of the 4th round.\n\nCohort B: Takes 0.15 mg\u002Fkg IV ATO for 3 rounds, then switches to 0.15 mg\u002Fkg Oral ATO for part of the 4th round.\n\nCohort C: Takes 0.15 mg\u002Fkg Oral ATO for all 4 rounds.\n\nAll cohorts also take 45 mg\u002Fm2\u002Fday ATRA during certain weeks of each round. Doctors will assess efficacy by checking bone marrow samples before and during treatment to see if the cancer is gone. Special lab tests will be used to look for cancer cells. Safety will be assessed by checking for side effects using blood tests, heart tests, physical exams, and other health checks. Quality of life will be assessed by the patients who will fill out surveys about how they feel during treatment and how much the side effects bother them. The study will also look at how often patients need to go to the doctor or hospital; how treatment affects daily life and work; and how satisfied patients are with their treatment.",[55,56,57,58,59,60,61,62,27],"Acute Promyelocytic Leukemia (APL)","Acute Promyelocytic Leukaemia","Acute Promyelocytic Leukemia With PML-RARA","Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","APL","Acute Promyelocytic Leukemia","Leukaemia","Leukemia Acute Promyelocytic Leukemia (APL)",[64,65],"Oral Arsenic Trioxide","Oral ATO","2025-12-25",{"date":68,"type":32},"2025-12-29",{"date":70,"type":21},"2026-01",{"date":72,"type":21},"2029-01",{"name":74,"class":75},"SDK Therapeutics, Inc.","INDUSTRY",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100337994","frailty-phenotype-assessments-to-optimize-treatment-strategies-for-older-patients-with-hematologic-malignancies-100337994","NCT03680677","Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies","Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies","Eligibility Criteria Arm A:\n\n* Age 60 years or older.\n* New diagnosis of Acute Leukemia or MDS, or suspected diagnosis.\n* Able to consent to the study.\n\nEligibility Criteria Arm B:\n\n* Age 60 years or older with a hematologic malignancy.\n* Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy.\n* Able to consent to the study.","60 Years",{"count":85,"type":21},20,"OBSERVATIONAL","The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.",[27,89],"MDS","RECRUITING","2025-07-29",{"date":93,"type":32},"2025-07-31",{"date":95,"type":32},"2018-09-21",{"date":97,"type":21},"2026-11",{"name":99,"class":39},"Abramson Cancer Center at Penn Medicine",1]